Hologic Company Profile (NASDAQ:HOLX)

About Hologic

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: HOLX
  • CUSIP: 43644010
Key Metrics:
  • Previous Close: $40.09
  • 50 Day Moving Average: $39.894
  • 200 Day Moving Average: $38.848
  • 52-Week Range: $32.64 - $41.24
  • Trailing P/E Ratio: 34.397
  • Foreward P/E Ratio: 19.09
  • P/E Growth: 2.390
  • Market Cap: $11.24B
  • Outstanding Shares: 279,296,000
  • Beta: 1.1
  • Net Margins: 11.57%
  • Return on Equity: 27.17%
  • Return on Assets: 7.86%
  • Debt-to-Equity Ratio: 1.17%
  • Current Ratio: 1.81%
  • Quick Ratio: 1.61%
Additional Links:
Companies Related to Hologic:

Analyst Ratings

Consensus Ratings for Hologic (NASDAQ:HOLX) (?)
Ratings Breakdown: 5 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $44.43 (10.82% upside)

Analysts' Ratings History for Hologic (NASDAQ:HOLX)
DateFirmActionRatingPrice TargetDetails
2/15/2017Needham & Company LLCUpgradeHold -> Buy$46.00View Rating Details
2/15/2017Bank of America CorpDowngradeBuy -> NeutralView Rating Details
2/5/2017BTIG ResearchReiterated RatingBuy$47.00View Rating Details
1/23/2017Canaccord GenuitySet Price TargetBuy$48.00View Rating Details
1/18/2017Deutsche Bank AGReiterated RatingBuy$48.00View Rating Details
1/8/2017Jefferies Group LLCReiterated RatingBuy$46.00View Rating Details
1/4/2017Evercore ISIDowngradeBuy -> Hold$42.00View Rating Details
1/4/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$44.00 -> $48.00View Rating Details
11/19/2016Barclays PLCSet Price TargetBuy$45.00View Rating Details
11/3/2016Leerink SwannReiterated RatingTop Pick$46.00 -> $43.00View Rating Details
8/1/2016RBC Capital MarketsReiterated RatingSector Perform$37.00 -> $39.00View Rating Details
8/1/2016Royal Bank Of CanadaBoost Price TargetSector Perform$37.00 -> $39.00View Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00View Rating Details
4/29/2016Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$45.00View Rating Details
1/31/2016William BlairReiterated RatingOutperformView Rating Details
1/28/2016J P Morgan Chase & CoReiterated RatingBuyView Rating Details
12/11/2015Stifel NicolausUpgradeHold -> Buy$45.00 -> $45.00View Rating Details
10/26/2015GabelliInitiated CoverageBuy$43.00View Rating Details
10/21/2015Craig HallumDowngradeBuy -> Hold$42.00 -> $37.00View Rating Details
8/3/2015ArgusReiterated RatingBuy$43.00 -> $52.00View Rating Details
7/13/2015Evercore Partners Inc.Reiterated RatingBuy -> HoldView Rating Details
7/1/2015Cowen and CompanyBoost Price TargetMarket Perform$35.00 -> $40.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Hologic (NASDAQ:HOLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.38$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Hologic (NASDAQ:HOLX)
Current Year EPS Consensus Estimate: $1.92 EPS
Next Year EPS Consensus Estimate: $2.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.45$0.46$0.45
Q2 20162$0.47$0.48$0.48
Q3 20165$0.47$0.48$0.47
Q4 20163$0.49$0.50$0.49
Q1 20174$0.50$0.51$0.51
Q2 20173$0.46$0.53$0.48
Q3 20173$0.47$0.54$0.49
Q4 20173$0.48$0.55$0.50
(Data provided by Zacks Investment Research)


Dividend History for Hologic (NASDAQ:HOLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hologic (NASDAQ:HOLX)
Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 94.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.42View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.36View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.05View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.88View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.66View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.68View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.00View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.00View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.84View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.54View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.26View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.60View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.80View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.50View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.00View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.00View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.00View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.20View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.80View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.32View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.68View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.03View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.90View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.00View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.40View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.00View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.28View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Hologic (NASDAQ:HOLX)
capitalcube.com logoHologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : February 21, 2017 (NASDAQ:HOLX)
us.rd.yahoo.com - February 22 at 12:49 PM
News IconHormel Foods Corp (NYSE:HRL), Hologic, Inc. (NASDAQ:HOLX) (NASDAQ:HOLX)
interiordesignfuture.com - February 18 at 5:11 PM
News IconAnalytical Guide for Reynolds American Inc. (RAI), Hologic, Inc. (HOLX) Stakeholders - The USA Commerce (NASDAQ:HOLX)
www.theusacommerce.com - February 17 at 3:22 PM
streetinsider.com logoHologic (HOLX) Announces FDA Grants PMA Approval for Aptima Hepatitis C Quant Dx Assay - StreetInsider.com (NASDAQ:HOLX)
www.streetinsider.com - February 17 at 3:22 PM
News IconAnalyst's Predictions on Discovery Communications, Inc. (DISCA), Hologic, Inc. (HOLX) - StockNewsJournal (NASDAQ:HOLX)
stocknewsjournal.com - February 17 at 3:22 PM
seekingalpha.com logoHologic To Acquire Cynosure For $1.65 Billion - Seeking Alpha (NASDAQ:HOLX)
seekingalpha.com - February 17 at 3:22 PM
us.rd.yahoo.com logoHologic downgraded by BofA/Merrill (NASDAQ:HOLX)
us.rd.yahoo.com - February 17 at 12:45 PM
4-traders.com logoS&P 500 Analyst Moves: HOLX (NASDAQ:HOLX)
www.4-traders.com - February 16 at 5:39 PM
investopedia.com logoHologic to Buy Cynosure for $1.65B (HOLX, CYNO) (NASDAQ:HOLX)
www.investopedia.com - February 16 at 5:39 PM
finance.yahoo.com logoFDA Grants PMA Approval for Hologic's Aptima® Hepatitis C Quant Dx Assay (NASDAQ:HOLX)
finance.yahoo.com - February 16 at 5:39 PM
finance.yahoo.com logo4:03 pm Hologic: FDA has granted PMA approval for its HCV assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther system (NASDAQ:HOLX)
finance.yahoo.com - February 16 at 5:39 PM
marketexclusive.com logoHOLOGIC,INC. (NASDAQ:HOLX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:HOLX)
marketexclusive.com - February 15 at 12:07 AM
us.rd.yahoo.com logoHologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses (NASDAQ:HOLX)
us.rd.yahoo.com - February 15 at 12:07 AM
us.rd.yahoo.com logoHologic to buy Cynosure for $1.65 bln (NASDAQ:HOLX)
us.rd.yahoo.com - February 15 at 12:07 AM
us.rd.yahoo.com logoUS STOCKS-Wall St flat ahead of Yellen testimony (NASDAQ:HOLX)
us.rd.yahoo.com - February 15 at 12:07 AM
News IconHot Stocks Report Tiffany & Co. (NYSE:TIF), Hologic, Inc. (NASDAQ ... - Post Analyst (NASDAQ:HOLX)
postanalyst.com - February 14 at 7:03 PM
News IconWhat Analysts are Predicting For Fidelity National Financial, Inc. (FNF), Hologic, Inc. (HOLX)? - The USA Commerce (NASDAQ:HOLX)
theusacommerce.com - February 14 at 7:03 PM
streetinsider.com logoHologic (HOLX) to Acquire Cynosure (CYNO) for $1.65B - StreetInsider.com (NASDAQ:HOLX)
www.streetinsider.com - February 14 at 7:03 PM
biz.yahoo.com logoHOLOGIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex (NASDAQ:HOLX)
biz.yahoo.com - February 14 at 7:03 PM
seekingalpha.com logoHologic takes out Cynosure for $1.65B ($66/share) (NASDAQ:HOLX)
seekingalpha.com - February 14 at 8:31 AM
News IconAnalyst's Indicator Review for Tyson Foods, Inc. (TSN), Hologic, Inc. (HOLX) - The USA Commerce (NASDAQ:HOLX)
theusacommerce.com - February 10 at 11:29 PM
News IconRevenue Approximations Analysis: Capital One Financial Corporation (COF), Hologic, Inc. (HOLX) - StockNewsJournal (NASDAQ:HOLX)
stocknewsjournal.com - February 9 at 6:37 PM
finance.yahoo.com logoHologic to Webcast Presentations at Upcoming Investor Conferences (NASDAQ:HOLX)
finance.yahoo.com - February 9 at 6:37 PM
News IconShares of Hologic, Inc. (HOLX) Sees Large Outflow of Money ... - Highland Mirror (NASDAQ:HOLX)
www.highlandmirror.com - February 8 at 11:21 PM
biz.yahoo.com logoHOLOGIC INC Files SEC form 10-Q, Quarterly Report (NASDAQ:HOLX)
biz.yahoo.com - February 8 at 6:20 PM
finance.yahoo.com logoHOLOGIC INC Financials (NASDAQ:HOLX)
finance.yahoo.com - February 8 at 6:20 PM
News IconWill Hologic Inc’s (HOLX) Earnings Grow In The Year Ahead? (NASDAQ:HOLX)
simplywall.st - February 5 at 5:28 PM
News IconIs It Time to go for EQT Corporation (EQT), Hologic, Inc. (HOLX)? - StockNewsJournal (NASDAQ:HOLX)
stocknewsjournal.com - February 4 at 5:45 PM
News IconKahn Brothers Group Inc De Cuts Position in Hologic (HOLX) by $48063797 - Highland Mirror (NASDAQ:HOLX)
www.highlandmirror.com - February 4 at 5:45 PM
News IconHow Does the Chart Look for Hologic, Inc. (HOLX) ? - The USA Commerce (NASDAQ:HOLX)
www.theusacommerce.com - February 4 at 5:45 PM
News IconHologic launches next-generation NovaSure ADVANCED global endometrial ablation system (NASDAQ:HOLX)
www.dotmed.com - February 3 at 6:18 PM
News IconThe UBS Group AG Increases Stake in Hologic Inc. (HOLX) (NASDAQ:HOLX)
prensariotiretail.com - February 3 at 4:23 AM
seekingalpha.com logoHologic launches new endometrial ablation system - Seeking Alpha (NASDAQ:HOLX)
seekingalpha.com - February 2 at 11:22 PM
us.rd.yahoo.com logoEdited Transcript of HOLX earnings conference call or presentation 1-Feb-17 9:30pm GMT (NASDAQ:HOLX)
us.rd.yahoo.com - February 2 at 6:20 PM
us.rd.yahoo.com logoHologic Launches Next-Generation NovaSure® ADVANCED Global Endometrial Ablation System for the Treatment of Abnormal Uterine Bleeding (NASDAQ:HOLX)
us.rd.yahoo.com - February 2 at 6:20 PM
capitalcube.com logoHologic, Inc. :HOLX-US: Earnings Analysis: Q1, 2017 By the Numbers : February 2, 2017 (NASDAQ:HOLX)
us.rd.yahoo.com - February 2 at 6:20 PM
seekingalpha.com logoHologic launches new endometrial ablation system (NASDAQ:HOLX)
seekingalpha.com - February 2 at 10:37 AM
seekingalpha.com logoHologic's (HOLX) CEO Steve MacMillan on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:HOLX)
seekingalpha.com - February 1 at 11:30 PM
nasdaq.com logoHologic Inc Announces 10% Gain In Q1 Profit - Nasdaq (NASDAQ:HOLX)
www.nasdaq.com - February 1 at 11:30 PM
rttnews.com logoHologic Inc Announces 10% Gain In Q1 Profit (NASDAQ:HOLX)
www.rttnews.com - February 1 at 6:25 PM
biz.yahoo.com logoQ1 2017 Hologic Inc Earnings Release - After Market Close (NASDAQ:HOLX)
us.rd.yahoo.com - February 1 at 6:25 PM
us.rd.yahoo.com logoHologic Announces Financial Results for First Quarter of Fiscal 2017 (NASDAQ:HOLX)
us.rd.yahoo.com - February 1 at 6:25 PM
us.rd.yahoo.com logo4:11 pm Hologic beats by $0.01, beats on revs; lowers FY17 guidance (NASDAQ:HOLX)
us.rd.yahoo.com - February 1 at 6:25 PM
sg.finance.yahoo.com logoHologic tops Street 1Q forecasts (NASDAQ:HOLX)
sg.finance.yahoo.com - February 1 at 6:25 PM
4-traders.com logoGrifols : closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million (NASDAQ:HOLX)
www.4-traders.com - January 31 at 6:26 PM
feeds.reuters.com logoBRIEF-Hologic completes divestiture of blood screening business (NASDAQ:HOLX)
feeds.reuters.com - January 31 at 5:19 PM
finance.yahoo.com logoAbiomed (ABMD) Beats Earnings & Revenue Estimates in Q3 (NASDAQ:HOLX)
finance.yahoo.com - January 30 at 11:15 AM
investornewswire.com logoHologic, Inc. (NASDAQ:HOLX) Records An Impact Score Of 68 - Investor Newswire (NASDAQ:HOLX)
www.investornewswire.com - January 28 at 5:53 PM
News IconEarnings in Full Force, Analysts Take Aim at Hologic, Inc. (NASDAQ:HOLX) - Wall Street Beacon (NASDAQ:HOLX)
wsbeacon.com - January 28 at 5:53 PM
us.rd.yahoo.com logoQuality Systems (QSII) Beats on Earnings & Revenues in Q3 (NASDAQ:HOLX)
us.rd.yahoo.com - January 27 at 7:40 PM


What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Where is Hologic's stock going? Where will Hologic's stock price be in 2017?

14 equities research analysts have issued 12-month target prices for Hologic's shares. Their predictions range from $39.00 to $48.00. On average, they anticipate Hologic's stock price to reach $44.43 in the next twelve months.

When will Hologic announce their earnings?

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • Needham & Company LLC analysts commented, "HOLX is acquiring Cynosure (CYNO) for $1.44B with an all-cash tender offer. CYNO is a leading aesthetics company that competes in a $2B market growing in the double-digits with a range of products used for hair removal, body contouring, skin revitalization, and other cosmetic procedures. HOLX expects CYNO to increase its revenue growth and add $0.13-0.15 to its FY18E EPS. HOLX has now effectively swapped a business with declining sales and margins (blood screening) for one with double-digit growth and improving margins (CYNO). With the blood screening EPS "hole" now partially filled and HOLX facing increasingly easy comps over the next three quarters, we upgrade to Buy." (2/15/2017)
  • According to Zacks Investment Research, "Hologic delivered solid first quarter 2017 with both earnings and revenues ahead of the Zacks Consensus Estimate. We note that, the share price of Hologic, which outpaced the Zacks categorized Medical Instruments industry over the past three months, continues to trend higher banking on a solid quarterly performance. Segment-wise, barring skeletal Health, Hologic witnessed positive growth across all its business segments. However, a dismal guidance for the rest of fiscal 2017 concerns us. The blood screening divestiture and a stronger U.S. dollar are expected to mar the company's growth momentum in the upcoming period. On an impressive note, the loss making blood screening divestment should increase the company’s financial flexibility. Strong cash balance position also encourages us. Moreover, despite higher expenses, Hologic observed margin expansion on strong domestic sales growth, favorable product mix, and operational improvement." (2/3/2017)

  • Barclays PLC analysts commented, "stronger for longer" versus its previous expectations.The brokerage, who also upped the price target by $2 to $44, believes the breast health business will be able to sustain its L-MSD growth with a longer 3D mammography tail, service growth from 3D conversions, and new product launches such as Affirm."Our FDA mammography market model improves our conviction in the durability of placements and Hologic share gains," analyst Jack Meehan wrote in a note.In addition, the Meehan said the company's Panther system strengthened its leadership position at the high-end of MDx workflows and can drive L-MSD growth for the entire diagnostics business alone.Related Link: New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting, Reversible Contraceptives List"The launch of the Fusion PCR sidecar in 2017/2018 will add additional flexibility to the instrument, which could lead to higher consumable pull-through, as the company expands its US menu beyond sexual health into virology," Meehan highlighted. Importantly, the analyst feels that Panther is "PAMA-proof" for upcoming Dx reimbursement changes, and could be an aggregator of share in a consolidating lab market. Further, the analyst expects at least HSD growth for the GYN Surgical unit from MyoSure strength."We believe that at current levels shares offer an attractive entry point, flat YTD versus the S&P 500 up 6 percent and our coverage universe up 15 percent," (9/23/2016)

Who owns Hologic stock?

Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.49%), Alyeska Investment Group L.P. (0.67%), Dimensional Fund Advisors LP (0.65%), Investec Asset Management LTD (0.61%), Franklin Resources Inc. (0.55%) and Renaissance Technologies LLC (0.52%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Wayne Wilson.

Who sold Hologic stock? Who is selling Hologic stock?

Hologic's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC, Tudor Investment Corp Et Al, AQR Capital Management LLC, Dimensional Fund Advisors LP, Guggenheim Capital LLC, Brown Advisory Inc., Oxford Asset Management and Ardevora Asset Management LLP. Company insiders that have sold Hologic stock in the last year include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming and Peter J Valenti III.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Investec Asset Management LTD, State Street Corp, Renaissance Technologies LLC, Asset Management One Co. Ltd., Marshall Wace LLP, Clough Capital Partners L P and Russell Investments Group Ltd..

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Hologic stock cost?

One share of Hologic stock can currently be purchased for approximately $40.09.

Hologic (NASDAQ:HOLX) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Earnings History Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Dividend History Chart

Dividend Payments by Quarter for Hologic (NASDAQ:HOLX)

Last Updated on 2/22/2017 by MarketBeat.com Staff